Neurocrine Biosciences Provides COVID-19 Business Update

About this update from Neurocrine Biosciences, Inc.

[{"type":"text","content":"SAN DIEGO, April 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers, healthcare providers and employees. The company continues to assess any potential impact to its business given the ongoing nature of the pandemic and plans to provide further updates during its first quarter financial results in early May.\n\n \n \n \n \n \n \n\n \nWorkplace and CommunityWe are committed to ensuring the safety and well-being of our employees and their families, as well as the communities in which we serve. In March, the company enacted new internal policies to protect its staff and mitigate the spread of COVID-19. \nTo minimize exposure, Neurocrine Biosciences implemented a \"Work from Home Policy\" for all employees except certain key essential members involved in business-critical activities. For business-critical employees, we have implemented safety measures designed to comply with federal, state, and local guidelines. Our customer-facing personnel are utilizing remote technologies to ensure continued support for patients and healthcare professionals. We have donated supplies to San Diego area hospitals to support our local community's preparedness and response to COVID-19.We will continue to assess the need to amend or expand existing policies given the fluidity of the situation. \nSupporting the Needs of Patients Taking INGREZZA® (valbenazine)At Neurocrine Biosciences, we are working to ensure that patients with tardive dyskinesia are well supported during this time and have uninterrupted access to INGREZZA. \nOur network of specialty and mental health pharmacies remains engaged with patients to fill prescriptions and support their overall health and well-being during these challenging times. We do not expect any disruption in our ability to supply patients with INGREZZA. In addition to having ample inventory, we have redundant manufacturing capabilities in place to further mitigate risk of INGREZZA supply disruption.Crinecerfont Phase II Data in Adults and Global Registrational Study UpdatesWe look forward to sharing data from the Phase II proof-of-concept study of crinecerfont in adults with classic congenital adrenal hyp...

More updates from Neurocrine Biosciences, Inc.